These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28528837)

  • 1. Re: Toy et al.: Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity (Ophthalmology. 2016;123:2166-2175).
    Chaudhary P; Das MK; Varshney A
    Ophthalmology; 2017 Jun; 124(6):e52-e53. PubMed ID: 28528837
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844).
    Blair MP; Shapiro MJ;
    Ophthalmology; 2017 Oct; 124(10):e74-e75. PubMed ID: 28938930
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
    Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
    Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the Editor: Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
    Mataftsi A; Koulali E; Papageorgiou E; Ziakas N; Brazitikos P
    Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):372. PubMed ID: 28499046
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab for Retinopathy of Prematurity: Treatment When Pathology Is Embedded in a Normally Developing Vascular System.
    Good WV
    Ophthalmology; 2016 Sep; 123(9):1843-4. PubMed ID: 27549875
    [No Abstract]   [Full Text] [Related]  

  • 7. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
    Mintz-Hittner HA
    J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750
    [No Abstract]   [Full Text] [Related]  

  • 8. Effective dose of bevacizumab for the treatment of retinopathy of prematurityResponse: effective dose of bevacizumab for the treatment of retinopathy of prematurityComputer-assisted digital ımage analysis of plus disease in retinopathy of prematurityRetinopathy of prematurityWhich döşe of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
    Şahin A; Türkcü FM; Şahin M
    Arq Bras Oftalmol; 2018; 81(4):354-356. PubMed ID: 29995132
    [No Abstract]   [Full Text] [Related]  

  • 9. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.
    Tseng CC; Chen SN; Hwang JF; Lin CJ
    J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmortem vitreous bevacizumab levels of an infant treated for retinopathy of prematurity.
    Hypes S; Nasser O; Hanna N; Lawhon W; Bouhenni R; Hertle RW
    J AAPOS; 2016 Dec; 20(6):537-539. PubMed ID: 27810420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Freedman et al: Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes (Ophthalmology. 2022;129:1120-1128).
    Asensio-Sánchez VM
    Ophthalmology; 2023 May; 130(5):e18. PubMed ID: 36702728
    [No Abstract]   [Full Text] [Related]  

  • 13. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
    Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
    Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
    Spandau U
    Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
    [No Abstract]   [Full Text] [Related]  

  • 16. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
    Ceylan OM; Dikçi S; Genc O; Yılmaz T
    Arq Bras Oftalmol; 2016; 79(4):279. PubMed ID: 27626160
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
    Mireskandari K; Collins ME; Tehrani N
    Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
    [No Abstract]   [Full Text] [Related]  

  • 20. REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study.
    Cernichiaro-Espinosa LA; Harper CA; Read SP; Wright LM; Scribbick FW; Young R; Negron CI; Rodríguez A; Berrocal AM
    Retina; 2018 Jun; 38(6):1251-1255. PubMed ID: 29689029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.